NCI-MATCH Searchable Treatment Arms Table

NCI-MATCH is a precision medicine cancer trial with 38 treatment arms. Each arm targets a unique, often rare, gene abnormality known to drive cancer growth. The trial closed to patient enrollment on December 23, 2022. There were a total of 1,201 patients enrolled across all treatment arms.

Below is a searchable list of all treatment arms and their status. Click on the links to access the published trial results. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.

We update this table on an ongoing basis as new publications appear.

GENOMIC TARGET(S) & DRUG(S)STATUS

ALK translocations - Arm F
ROS1 translocations - Arm G

Drug: crizotinib 
Arms F & G

Published

AKT mutations

Drug: capivasertib
Arm Y

Published

BRAF fusions or non-V600E, non-V600K BRAF mutations

Drug: trametinib
Arm R

Published

BRAF V600E or BRAF V600K mutations
Drugs: dabrafenib + trametinib
Arm H

Published

CCND1, 2, and 3 amplifications and Rb protein expression by immunohistochemistry

Drug: palbociclib
Arm Z1B

Published

FGFR pathway aberrations

Drug: AZD4547
Arm W

Published

GNAQ or GNA11 mutations - Arm S2
NF1 mutations - Arm S1

Drug: trametinib
Arm S2 and S1

Published

HER2 activating mutations

Drug: afatinib
Arm B

Published

HER2 amplification

Drugs: trastuzumab + pertuzumab
Arm J

Published

HER2 amplification

Drug: ado-trastuzumab emtansine
Arm Q

Published

LAG-3 expression with MMR deficiency

Drug: nivolumab
Arm Z1D

Published

NRAS mutations

Drug: binimetinib
Arm Z1A

Published

PIK3CA mutation with or without PTEN loss

Drug: copanlisib
Arm Z1F

Published

PIK3CA mutation without RAS mutation or PTEN loss

Drug: taselisib 
Arm I

Published
AKT mutations
Drug: ipatasertib 
Arm Z1K
Manuscript in progress
BRAF Non-V600 mutations
Drug: ulixertinib
Arm Z1L
Manuscript in progress

BRCA1 or BRCA2 mutations
Drug: adavosertib

Arm Z1I

Manuscript in progress
CDK4 or CDK6 amplification
Drug: palbociclib
Arm Z1C
Manuscript in progress
cKIT mutations; PDGFRA or PDGFRB variants and fusions
Drug: sunitinib malate
Arm V
Manuscript in progress
EGFR-activating mutations
Drug: afatinib
Arm A
Manuscript in progress
EGFR T790M (with/without an activating mutation) or rare activating mutations of EGFR
Drug: osimertinib
Arm E
Manuscript in progress

FGFR amplification

Drug: erdafitinib
Arm K1

Manuscript in progress

FGFR mutations or fusions

Drug: erdafitinib
Arm K2

Manuscript in progress
MET amplification - Arm C1
MET exon 14 deletion - Arm C2
Drug: crizotinib
Arms C1 & C2
Manuscript in progress

mTOR, KEAP1 or NFE2L2 mutations - Arm L
TSC1 or TSC2 mutations - Arm M
Drug: sapanisertib
Arms L & M

 

Manuscript in progress

NF2 loss
Drug: defactinib 
Arm U

 

Manuscript in progress
NTRK fusions
Drug: larotrectinib 
Arm Z1E
Manuscript in progress

PTEN (deleterious) seq result and PTEN expression by immunohistochemistry

Drug: copanlisib
Arm Z1H

Manuscript in progress

PTEN loss by immunohistochemistry - Arm P
PTEN mutations or deletions, with PTEN expression on immunohistochemistry  - Arm N
Drug: GSK2636771
Arms: P & N

Manuscript in progress
PTEN mutations (except for a Copy Number=0) and PTEN negative by Immunohistochemistry
Drug: copanlisib
Arm Z1G
Manuscript in progress
Smoothened (SMO) or patched 1 (PTCH1) mutations
Drug: vismodegib
Arm T
Manuscript in progress
DDR2 mutations
Drug: dasatinib
Arm X
Closed

LAG-3 expression with microsatellite instability (MSI)
Drugs: relatlimab + nivolumab
Arm Z1M

Closed

ECOG-ACRIN Cancer Research Group